RxDoctor Payments Data

Jennifer Henley

Family · Jackson, MSNPI 1578037172

Payments from drug & device makers

$1,091in general payments, 2019–2025

Across 27 payments — averaging $40.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$413
  • Gilead$140
  • Lilly USA, LLC$129
  • Bayer$125
  • Boehringer Ingelheim$117
  • AbbVie$97
  • plus $70 from 2 others

What the payments were for

  • Food & beverage$1,091100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk13$413
Gilead2$140
Lilly USA, LLC4$129
Bayer1$125
Boehringer Ingelheim2$117
AbbVie1$97
Merck2$40
AstraZeneca2$30

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,091 in reported general payments places this provider in the 70th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$498
Medicare patients
25
Services billed
68

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin37$49,468
OzempicSemaglutide13$28,095
RybelsusSemaglutide11$25,654
TrulicityDulaglutide15$20,410
JentaduetoLinagliptin/Metformin Hcl14$15,724
JanuviaSitagliptin Phosphate13$12,889
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$9,123
Atorvastatin Calcium330$3,122
Lantus SolostarInsulin Glargine,hum.Rec.Anlog22$2,154
Amlodipine Besylate359$2,052
Albuterol Sulfate HfaAlbuterol Sulfate60$1,660
Nifedipine ErNifedipine41$1,387
Losartan Potassium148$1,118
Pantoprazole Sodium77$948
Hydralazine Hcl52$828

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Jentadueto$117$65,19251 claims
Novo NordiskOzempic, Rybelsus$413$53,74924 claims
Lilly USA, LLCTrulicity$129$20,41015 claims
MerckJanuvia$40$12,88913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,007 family providers in Mississippi.

Other family in Jackson

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →